Needham & Company LLC Raises Personalis (NASDAQ:PSNL) Price Target to $7.25

Personalis (NASDAQ:PSNL) had its target price raised by Needham & Company LLC from $5.50 to $7.25 in a report released on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, Lake Street Capital assumed coverage on Personalis in a research report on Tuesday, April 30th. They issued a buy rating and a $4.00 price objective for the company.

Personalis Stock Performance

PSNL opened at $5.99 on Friday. The firm’s fifty day moving average is $2.35 and its two-hundred day moving average is $1.75. The firm has a market cap of $317.95 million, a PE ratio of -3.15 and a beta of 1.85. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. The business had revenue of $22.58 million during the quarter, compared to analysts’ expectations of $19.81 million. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. During the same quarter in the prior year, the company earned ($0.50) EPS. Equities analysts forecast that Personalis will post -1.12 EPS for the current fiscal year.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in shares of Personalis during the first quarter worth about $29,000. Virtu Financial LLC bought a new position in shares of Personalis during the 1st quarter worth approximately $41,000. Quadrature Capital Ltd bought a new position in shares of Personalis during the 4th quarter worth approximately $152,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Personalis by 58.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock valued at $142,000 after purchasing an additional 34,900 shares during the last quarter. Finally, Howland Capital Management LLC lifted its position in shares of Personalis by 392.8% in the first quarter. Howland Capital Management LLC now owns 211,118 shares of the company’s stock worth $315,000 after purchasing an additional 168,274 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.